查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1360313

細胞分析市場 - 2023-2031 年全球產業分析、規模、佔有率、成長、趨勢和預測

Cell Analysis Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031
出版日期: | 出版商: Transparency Market Research | 英文 166 Pages | 商品交期: 2-10個工作天內

價格

細胞分析市場 - 報告範圍

TMR 關於全球細胞分析市場的報告研究了過去以及當前的成長趨勢和機會，以獲得 2023 年至 2031 年預測期內市場指標的寶貴見解。該報告提供了全球細胞分析市場的收入2017-2031年期間，考慮2023年為基準年，2031年為預測年。報告也提供了2023年至2031年全球細胞分析市場的年複合成長率（CAGR%）。

該報告是經過廣泛研究後編寫的。初級研究涉及大部分研究工作，其中分析師對關鍵意見領袖、行業領導者和輿論製造者進行了採訪。二次研究涉及參考主要參與者的產品文獻、年度報告、新聞稿和相關文件，以了解細胞分析市場。

市場概況
2023年市場價值 190 億美元
2031 年市場價值 424 億美元
複合年成長率 9.2%

該報告深入探討了全球細胞分析市場的競爭格局。全球細胞分析市場的主要參與者已被確定，並且每一位參與者都已根據各種屬性進行了分析。公司概況、財務狀況、最新發展和 SWOT 是本報告中介紹的全球細胞分析市場參與者的屬性。

目錄

第 1 章：前言

第 2 章：假設與研究方法

第 3 章：市場概覽

  • 概述
  • 市場動態
  • 按治療領域分類的主要生物技術和製藥公司研發支出概覽

第 4 章：全球細胞分析市場分析與預測：按最終用戶

  • 簡介與定義
  • 主要發現/進展
  • 市場價值預測：按最終用戶，2017-2031
    • 生技與製藥公司
    • 學術界
    • 化妝品產業
    • 合約研究組織
    • 合約開發和製造組織

第 5 章：全球市場分析與預測：按治療領域

  • 簡介與定義
  • 主要發現/進展
  • 市場價值預測：依治療領域，2015-2031
    • 腫瘤學和免疫腫瘤學
      • 小分子
      • 以蛋白質為基礎的治療
      • 細胞療法
      • 核酸類藥物
    • 心血管及代謝疾病
      • 小分子
      • 以蛋白質為基礎的治療
      • 細胞療法
      • 核酸類藥物
    • 免疫學
      • 小分子
      • 以蛋白質為基礎的治療
      • 細胞療法
      • 核酸類藥物
    • 罕見疾病
      • 小分子
      • 以蛋白質為基礎的治療
      • 細胞療法
      • 核酸類藥物
    • 神經系統疾病
      • 小分子
      • 以蛋白質為基礎的治療
      • 細胞療法
      • 核酸類藥物
    • 其他
      • 小分子
      • 以蛋白質為基礎的治療
      • 細胞療法
      • 核酸類藥物

第 6 章：全球市場分析與預測：依技術分類

  • 簡介與定義
  • 主要發現/進展
  • 市場價值預測：依技術分類，2017-2031
    • 流式細胞儀
    • 基於圖像的細胞計數
    • 生化檢測
    • 質譜

第 7 章：全球市場分析與預測：按工作場所

  • 簡介與定義
  • 主要發現/進展
  • 市場價值預測：依工作場所分類，2017-2031
    • 目標識別
    • 命中生成和線索識別
    • 潛在客戶最佳化
    • 體外臨床前研究
    • 體內臨床前研究
    • 臨床研究

第 8 章：全球市場分析與預測：按國家分類

  • 主要發現
  • 市場價值預測：依國家分類，2017-2031
    • 美國
    • 歐洲
    • 中國
    • 世界其他地區

第 9 章：美國細胞分析市場分析與預測

第 10 章：歐洲細胞分析市場分析與預測

第 11 章：中國細胞分析市場分析與預測

第 12 章：世界其他地區細胞分析市場分析與預測

Product Code: TMRGL12221

Cell Analysis Market - Scope of Report

TMR's report on the global cell analysis market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global cell analysis market for the period 2017-2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global cell analysis market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the cell analysis market.

Market Snapshot
Market Value in 2023US$ 19 Bn
Market Value in 2031US$ 42.4 Bn
CAGR9.2%

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global cell analysis market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global cell analysis market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global cell analysis market.

The report delves into the competitive landscape of the global cell analysis market. Key players operating in the global cell analysis market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global cell analysis market profiled in this report.

Key Questions Answered in Global Cell Analysis Market Report:

  • What is the sales/revenue generated by cell analysis across all regions during the forecast period?
  • What are the opportunities in the global cell analysis market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2031?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?

Cell Analysis Market - Research Objectives and Research Approach

The comprehensive report on the global cell analysis market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global cell analysis market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global cell analysis market.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Key Research Objectives

2. Assumptions and Research Methodology

3. Market Overview

  • 3.1. Overview
  • 3.2. Market Dynamics
    • 3.2.1. Drivers
    • 3.2.2. Restraints
    • 3.2.3. Opportunities
  • 3.3. Overview on R&D spending of major biotechnology and pharmaceutical companies by therapeutic area
    • 3.3.1. Top 15 Origins of Pipeline Drugs
    • 3.3.2. Biological versus non-biological drugs as a % of pipeline
    • 3.3.3. Ongoing rise of gene and cell therapy

4. Global Cell Analysis Market Analysis and Forecast, by End-user

  • 4.1. Introduction & Definition
  • 4.2. Key Findings/Developments
  • 4.3. Market Value Forecast, by End-user, 2017-2031
    • 4.3.1. Biotechnology & Pharmaceutical Companies
    • 4.3.2. Academia
    • 4.3.3. Cosmetic Industry
    • 4.3.4. Contract Research Organizations
    • 4.3.5. Contract Development and Manufacturing Organizations

5. Global Biotechnology & Pharmaceutical Companies Cell Analysis Market Analysis and Forecast, by Therapeutic Area

  • 5.1. Introduction & Definition
  • 5.2. Key Findings/Developments
  • 5.3. Market Value Forecast, by Therapeutic Area, 2015-2031
    • 5.3.1. Oncology & Immune-oncology
      • 5.3.1.1. Small Molecules
      • 5.3.1.2. Protein-based Therapeutics
      • 5.3.1.3. Cell Therapy
      • 5.3.1.4. Nucleic Acid-based Drugs
    • 5.3.2. Cardiovascular & Metabolic Diseases
      • 5.3.2.1. Small Molecules
      • 5.3.2.2. Protein-based Therapeutics
      • 5.3.2.3. Cell Therapy
      • 5.3.2.4. Nucleic Acid-based Drugs
    • 5.3.3. Immunology
      • 5.3.3.1. Small Molecules
      • 5.3.3.2. Protein-based Therapeutics
      • 5.3.3.3. Cell Therapy
      • 5.3.3.4. Nucleic Acid-based Drugs
    • 5.3.4. Rare Diseases
      • 5.3.4.1. Small Molecules
      • 5.3.4.2. Protein-based Therapeutics
      • 5.3.4.3. Cell Therapy
      • 5.3.4.4. Nucleic Acid-based Drugs
    • 5.3.5. Neurological Diseases
      • 5.3.5.1. Small Molecules
      • 5.3.5.2. Protein-based Therapeutics
      • 5.3.5.3. Cell Therapy
      • 5.3.5.4. Nucleic Acid-based Drugs
    • 5.3.6. Others
      • 5.3.6.1. Small Molecules
      • 5.3.6.2. Protein-based Therapeutics
      • 5.3.6.3. Cell Therapy
      • 5.3.6.4. Nucleic Acid-based Drugs

6. Global Biotechnology & Pharmaceutical Companies Cell Analysis Market Analysis and Forecast, by Technology

  • 6.1. Introduction & Definition
  • 6.2. Key Findings/Developments
  • 6.3. Market Value Forecast, by Technology, 2017-2031
    • 6.3.1. Flow Cytometry
    • 6.3.2. Image-based Cytometry
    • 6.3.3. Biochemical Assays
    • 6.3.4. Mass Spectrometry

7. Global Biotechnology & Pharmaceutical Companies Cell Analysis Market Analysis and Forecast, by Workplace

  • 7.1. Introduction & Definition
  • 7.2. Key Findings/Developments
  • 7.3. Market Value Forecast, by Workplace, 2017-2031
    • 7.3.1. Target Identification
    • 7.3.2. Hit Generation & Lead Identification
    • 7.3.3. Lead Optimization
    • 7.3.4. In Vitro Preclinical Studies
    • 7.3.5. In Vivo Preclinical Studies
    • 7.3.6. Clinical Studies

8. Global Biotechnology & Pharmaceutical Companies Cell Analysis Market Analysis and Forecast, by Country/Region

  • 8.1. Key Findings
  • 8.2. Market Value Forecast, by Country/Region, 2017-2031
    • 8.2.1. U.S.
    • 8.2.2. Europe
    • 8.2.3. China
    • 8.2.4. Rest of the World

9. U.S. Cell Analysis Market Analysis and Forecast

  • 9.1. Introduction
    • 9.1.1. Key Findings
  • 9.2. Market Value Forecast, by End-user, 2017-2031
    • 9.2.1. Biotechnology & Pharmaceutical Companies
    • 9.2.2. Academia
    • 9.2.3. Cosmetic Industry
    • 9.2.4. Contract Research Organizations
    • 9.2.5. Contract Development and Manufacturing Organizations
  • 9.3. Biotechnology & Pharmaceutical Companies Market Value Forecast, by Therapeutic Area, 2017-2031
    • 9.3.1. Oncology & Immune-oncology
      • 9.3.1.1. Small Molecules
      • 9.3.1.2. Protein-based Therapeutics
      • 9.3.1.3. Cell Therapy
      • 9.3.1.4. Nucleic Acid-based Drugs
    • 9.3.2. Cardiovascular & Metabolic Diseases
      • 9.3.2.1. Small Molecules
      • 9.3.2.2. Protein-based Therapeutics
      • 9.3.2.3. Cell Therapy
      • 9.3.2.4. Nucleic Acid-based Drugs
    • 9.3.3. Immunology
      • 9.3.3.1. Small Molecules
      • 9.3.3.2. Protein-based Therapeutics
      • 9.3.3.3. Cell Therapy
      • 9.3.3.4. Nucleic Acid-based Drugs
    • 9.3.4. Rare Diseases
      • 9.3.4.1. Small Molecules
      • 9.3.4.2. Protein-based Therapeutics
      • 9.3.4.3. Cell Therapy
      • 9.3.4.4. Nucleic Acid-based Drugs
    • 9.3.5. Neurological Diseases
      • 9.3.5.1. Small Molecules
      • 9.3.5.2. Protein-based Therapeutics
      • 9.3.5.3. Cell Therapy
      • 9.3.5.4. Nucleic Acid-based Drugs
    • 9.3.6. Others
      • 9.3.6.1. Small Molecules
      • 9.3.6.2. Protein-based Therapeutics
      • 9.3.6.3. Cell Therapy
      • 9.3.6.4. Nucleic Acid-based Drugs
  • 9.4. Biotechnology & Pharmaceutical Companies Market Value Forecast, by Technology, 2017-2031
    • 9.4.1. Flow Cytometry
    • 9.4.2. Image-based Cytometry
    • 9.4.3. Biochemical Assays
    • 9.4.4. Mass Spectrometry
  • 9.5. Biotechnology & Pharmaceutical Companies Market Value Forecast, by Workplace, 2017-2031
    • 9.5.1. Target Identification
    • 9.5.2. Hit Generation & Lead Identification
    • 9.5.3. Lead Optimization
    • 9.5.4. In Vitro Preclinical Studies
    • 9.5.5. In Vivo Preclinical Studies
    • 9.5.6. Clinical Studies

10. Europe Cell Analysis Market Analysis and Forecast

  • 10.1. Introduction
    • 10.1.1. Key Findings
  • 10.2. Market Value Forecast, by End-user, 2017-2031
    • 10.2.1. Biotechnology & Pharmaceutical Companies
    • 10.2.2. Academia
    • 10.2.3. Cosmetic Industry
    • 10.2.4. Contract Research Organizations
    • 10.2.5. Contract Development and Manufacturing Organizations
  • 10.3. Biotechnology & Pharmaceutical Companies Market Value Forecast, by Therapeutic Area, 2017-2031
    • 10.3.1. Oncology & Immune-oncology
      • 10.3.1.1. Small Molecules
      • 10.3.1.2. Protein-based Therapeutics
      • 10.3.1.3. Cell Therapy
      • 10.3.1.4. Nucleic Acid-based Drugs
    • 10.3.2. Cardiovascular & Metabolic Diseases
      • 10.3.2.1. Small Molecules
      • 10.3.2.2. Protein-based Therapeutics
      • 10.3.2.3. Cell Therapy
      • 10.3.2.4. Nucleic Acid-based Drugs
    • 10.3.3. Immunology
      • 10.3.3.1. Small Molecules
      • 10.3.3.2. Protein-based Therapeutics
      • 10.3.3.3. Cell Therapy
      • 10.3.3.4. Nucleic Acid-based Drugs
    • 10.3.4. Rare Diseases
      • 10.3.4.1. Small Molecules
      • 10.3.4.2. Protein-based Therapeutics
      • 10.3.4.3. Cell Therapy
      • 10.3.4.4. Nucleic Acid-based Drugs
    • 10.3.5. Neurological Diseases
      • 10.3.5.1. Small Molecules
      • 10.3.5.2. Protein-based Therapeutics
      • 10.3.5.3. Cell Therapy
      • 10.3.5.4. Nucleic Acid-based Drugs
    • 10.3.6. Others
      • 10.3.6.1. Small Molecules
      • 10.3.6.2. Protein-based Therapeutics
      • 10.3.6.3. Cell Therapy
      • 10.3.6.4. Nucleic Acid-based Drugs
  • 10.4. Biotechnology & Pharmaceutical Companies Market Value Forecast, by Technology, 2017-2031
    • 10.4.1. Flow Cytometry
    • 10.4.2. Image-based Cytometry
    • 10.4.3. Biochemical Assays
    • 10.4.4. Mass Spectrometry
  • 10.5. Biotechnology & Pharmaceutical Companies Market Value Forecast, by Workplace, 2017-2031
    • 10.5.1. Target Identification
    • 10.5.2. Hit Generation & Lead Identification
    • 10.5.3. Lead Optimization
    • 10.5.4. In Vitro Preclinical Studies
    • 10.5.5. In Vivo Preclinical Studies
    • 10.5.6. Clinical Studies
  • 10.6. Biotechnology & Pharmaceutical Companies Market Value Forecast, by Country/Sub-region, 2017-2031
    • 10.6.1. EU5
    • 10.6.2. U.K.
    • 10.6.3. Switzerland
    • 10.6.4. Rest of Europe

11. China Cell Analysis Market Analysis and Forecast

  • 11.1. Introduction
    • 11.1.1. Key Findings
  • 11.2. Market Value Forecast, by End-user, 2017-2031
    • 11.2.1. Biotechnology & Pharmaceutical Companies
    • 11.2.2. Academia
    • 11.2.3. Cosmetic Industry
    • 11.2.4. Contract Research Organizations
    • 11.2.5. Contract Development and Manufacturing Organizations
  • 11.3. Biotechnology & Pharmaceutical Companies Market Value Forecast, by Therapeutic Area, 2017-2031
    • 11.3.1. Oncology & Immune-oncology
      • 11.3.1.1. Small Molecules
      • 11.3.1.2. Protein-based Therapeutics
      • 11.3.1.3. Cell Therapy
      • 11.3.1.4. Nucleic Acid-based Drugs
    • 11.3.2. Cardiovascular & Metabolic Diseases
      • 11.3.2.1. Small Molecules
      • 11.3.2.2. Protein-based Therapeutics
      • 11.3.2.3. Cell Therapy
      • 11.3.2.4. Nucleic Acid-based Drugs
    • 11.3.3. Immunology
      • 11.3.3.1. Small Molecules
      • 11.3.3.2. Protein-based Therapeutics
      • 11.3.3.3. Cell Therapy
      • 11.3.3.4. Nucleic Acid-based Drugs
    • 11.3.4. Rare Diseases
      • 11.3.4.1. Small Molecules
      • 11.3.4.2. Protein-based Therapeutics
      • 11.3.4.3. Cell Therapy
      • 11.3.4.4. Nucleic Acid-based Drugs
    • 11.3.5. Neurological Diseases
      • 11.3.5.1. Small Molecules
      • 11.3.5.2. Protein-based Therapeutics
      • 11.3.5.3. Cell Therapy
      • 11.3.5.4. Nucleic Acid-based Drugs
    • 11.3.6. Others
      • 11.3.6.1. Small Molecules
      • 11.3.6.2. Protein-based Therapeutics
      • 11.3.6.3. Cell Therapy
      • 11.3.6.4. Nucleic Acid-based Drugs
  • 11.4. Biotechnology & Pharmaceutical Companies Market Value Forecast, by Technology, 2017-2031
    • 11.4.1. Flow Cytometry
    • 11.4.2. Image-based Cytometry
    • 11.4.3. Biochemical Assays
    • 11.4.4. Mass Spectrometry
  • 11.5. Biotechnology & Pharmaceutical Companies Market Value Forecast, by Workplace, 2017-2031
    • 11.5.1. Target Identification
    • 11.5.2. Hit Generation & Lead Identification
    • 11.5.3. Lead Optimization
    • 11.5.4. In Vitro Preclinical Studies
    • 11.5.5. In Vivo Preclinical Studies
    • 11.5.6. Clinical Studies

12. Rest of the World Cell Analysis Market Analysis and Forecast

  • 12.1. Introduction
    • 12.1.1. Key Findings
  • 12.2. Market Value Forecast, by End-user, 2017-2031
    • 12.2.1. Biotechnology & Pharmaceutical Companies
    • 12.2.2. Academia
    • 12.2.3. Cosmetic Industry
    • 12.2.4. Contract Research Organizations
    • 12.2.5. Contract Development and Manufacturing Organizations
  • 12.3. Biotechnology & Pharmaceutical Companies Market Value Forecast, by Therapeutic Area, 2017-2031
    • 12.3.1. Oncology & Immune-oncology
      • 12.3.1.1. Small Molecules
      • 12.3.1.2. Protein-based Therapeutics
      • 12.3.1.3. Cell Therapy
      • 12.3.1.4. Nucleic Acid-based Drugs
    • 12.3.2. Cardiovascular & Metabolic Diseases
      • 12.3.2.1. Small Molecules
      • 12.3.2.2. Protein-based Therapeutics
      • 12.3.2.3. Cell Therapy
      • 12.3.2.4. Nucleic Acid-based Drugs
    • 12.3.3. Immunology
      • 12.3.3.1. Small Molecules
      • 12.3.3.2. Protein-based Therapeutics
      • 12.3.3.3. Cell Therapy
      • 12.3.3.4. Nucleic Acid-based Drugs
    • 12.3.4. Rare Diseases
      • 12.3.4.1. Small Molecules
      • 12.3.4.2. Protein-based Therapeutics
      • 12.3.4.3. Cell Therapy
      • 12.3.4.4. Nucleic Acid-based Drugs
    • 12.3.5. Neurological Diseases
      • 12.3.5.1. Small Molecules
      • 12.3.5.2. Protein-based Therapeutics
      • 12.3.5.3. Cell Therapy
      • 12.3.5.4. Nucleic Acid-based Drugs
    • 12.3.6. Others
      • 12.3.6.1. Small Molecules
      • 12.3.6.2. Protein-based Therapeutics
      • 12.3.6.3. Cell Therapy
      • 12.3.6.4. Nucleic Acid-based Drugs
  • 12.4. Biotechnology & Pharmaceutical Companies Market Value Forecast, by Technology, 2017-2031
    • 12.4.1. Flow Cytometry
    • 12.4.2. Image-based Cytometry
    • 12.4.3. Biochemical Assays
    • 12.4.4. Mass Spectrometry
  • 12.5. Biotechnology & Pharmaceutical Companies Market Value Forecast, by Workplace, 2017-2031
    • 12.5.1. Target Identification
    • 12.5.2. Hit Generation & Lead Identification
    • 12.5.3. Lead Optimization
    • 12.5.4. In Vitro Preclinical Studies
    • 12.5.5. In Vivo Preclinical Studies
    • 12.5.6. Clinical Studies

List of Tables

  • Table 01: Overview on R&D spending of major biotechnology and pharmaceutical companies, by therapeutic areas (1/4)
  • Table 02: Overview on R&D spending of major biotechnology and pharmaceutical companies, by therapeutic areas (2/4)
  • Table 03: Overview on R&D spending of major biotechnology and pharmaceutical companies, by therapeutic areas (2/3)
  • Table 04: Overview on R&D spending of major biotechnology and pharmaceutical companies, by therapeutic areas (4/4)
  • Table 05: Top 15 Origins of Pipeline Drugs
  • Table 06: Global Cell Analysis Market Value (US$ Mn) Forecast, by End-user, 2017-2031
  • Table 07: Global Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Therapeutic Area, 2017-2031
  • Table 08: Global Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Oncology & Immune-oncology, 2017-2031
  • Table 09: Global Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Cardiovascular & Metabolic Diseases, 2017-2031
  • Table 10: Global Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Immunology, 2017-2031
  • Table 11: Global Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Rare Diseases, 2017-2031
  • Table 12: Global Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Neurological Diseases, 2017-2031
  • Table 13: Global Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Others, 2017-2031
  • Table 14: Global Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Technology, 2017-2031
  • Table 15: Global Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Workplace, 2017-2031
  • Table 16: Global Cell Analysis Market Value (US$ Mn) Forecast, by Region, 2017-2031
  • Table 17: U.S. Cell Analysis Market Value (US$ Mn) Forecast, by End-user, 2017-2031
  • Table 18: U.S. Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Therapeutic Area, 2017-2031
  • Table 19: U.S. Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Oncology & Immune-oncology, 2017-2031
  • Table 20: U.S. Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Cardiovascular & Metabolic Diseases, 2017-2031
  • Table 21: U.S. Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Immunology, 2017-2031
  • Table 22: U.S. Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Rare Diseases, 2017-2031
  • Table 23: U.S. Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Neurological Diseases, 2017-2031
  • Table 24: U.S. Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Others, 2017-2031
  • Table 25: U.S. Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Technology, 2017-2031
  • Table 26: U.S. Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Workplace, 2017-2031
  • Table 27: Europe Cell Analysis Market Value (US$ Mn) Forecast, by End-user, 2017-2031
  • Table 28: Europe Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Therapeutic Area, 2017-2031
  • Table 29: Europe Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Oncology & Immune-oncology, 2017-2031
  • Table 30: Europe Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Cardiovascular & Metabolic Diseases, 2017-2031
  • Table 31: Europe Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Immunology, 2017-2031
  • Table 32: Europe Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Rare Diseases, 2017-2031
  • Table 33: Europe Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Neurological Diseases, 2017-2031
  • Table 34: Europe Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Others, 2017-2031
  • Table 35: Europe Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Technology, 2017-2031
  • Table 36: Europe Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Workplace, 2017-2031
  • Table 37: Europe Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 38: China Cell Analysis Market Value (US$ Mn) Forecast, by End-user, 2017-2031
  • Table 39: China Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Therapeutic Area, 2017-2031
  • Table 40: China Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Oncology & Immune-oncology, 2017-2031
  • Table 41: China Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Cardiovascular & Metabolic Diseases, 2017-2031
  • Table 42: China Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Immunology, 2017-2031
  • Table 43: China Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Rare Diseases, 2017-2031
  • Table 44: China Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Neurological Diseases, 2017-2031
  • Table 45: China Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Others, 2017-2031
  • Table 46: China Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Technology, 2017-2031
  • Table 47: China Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Workplace, 2017-2031
  • Table 48: Rest of the World Cell Analysis Market Value (US$ Mn) Forecast, by End-user, 2017-2031
  • Table 49: Rest of the World Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Therapeutic Area, 2017-2031
  • Table 50: China Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Oncology & Immune-oncology, 2017-2031
  • Table 51: Rest of the World Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Cardiovascular & Metabolic Diseases, 2017-2031
  • Table 52: Rest of the World Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Immunology, 2017-2031
  • Table 53: Rest of the World Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Rare Diseases, 2017-2031
  • Table 54: Rest of the World Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Neurological Diseases, 2017-2031
  • Table 55: Rest of the World Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Others, 2017-2031
  • Table 56: Rest of the World Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Technology, 2017-2031
  • Table 57: Rest of the World Biotechnology & Pharmaceutical Companies Cell Analysis Market Value (US$ Mn) Forecast, by Workplace, 2017-2031

List of Figures

  • Figure 01: Major R&D spending therapeutic areas, by companies
  • Figure 02: Biological versus non-biological drugs as a % of pipeline
  • Figure 03: Ongoing rise of gene and cell therapy
  • Figure 04: Global Cell Analysis Market Value Share Analysis, by End-user, 2022 and 2031
  • Figure 05: Global Cell Analysis Market Attractiveness Analysis, by End-user, 2023-2031
  • Figure 06: Global Cell Analysis Market (US$ Mn), by Biotechnology & Pharmaceutical Companies, 2017-2031
  • Figure 07: Global Cell Analysis Market (US$ Mn), by Academia, 2017-2031
  • Figure 08: Global Cell Analysis Market (US$ Mn), by Cosmetic Industry, 2017-2031
  • Figure 09: Global Cell Analysis Market (US$ Mn), by Contract Research Organizations, 2017-2031
  • Figure 10: Global Cell Analysis Market (US$ Mn), by Contract Development and Manufacturing Organizations, 2017-2031
  • Figure 11: Global Biotechnology & Pharmaceutical Companies Cell Analysis Market Value Share Analysis, by Therapeutic Area, 2022 and 2031
  • Figure 12: Global Biotechnology & Pharmaceutical Companies Cell Analysis Market Attractiveness Analysis, by Therapeutic Area, 2023-2031
  • Figure 13: Global Biotechnology & Pharmaceutical Companies Cell Analysis Market (US$ Mn), by Oncology & Immune-oncology, 2017-2031
  • Figure 14: Global Biotechnology & Pharmaceutical Companies Cell Analysis Market (US$ Mn), by Cardiovascular & Metabolic Diseases, 2017-2031
  • Figure 15: Global Biotechnology & Pharmaceutical Companies Cell Analysis Market (US$ Mn), by Immunology, 2017-2031
  • Figure 16: Global Biotechnology & Pharmaceutical Companies Cell Analysis Market (US$ Mn), by Rare Diseases, 2017-2031
  • Figure 17: Global Biotechnology & Pharmaceutical Companies Cell Analysis Market (US$ Mn), by Neurological Diseases, 2017-2031
  • Figure 18: Global Biotechnology & Pharmaceutical Companies Cell Analysis Market (US$ Mn), by Others, 2017-2031
  • Figure 19: Global Biotechnology & Pharmaceutical Companies Cell Analysis Market Value Share Analysis, by Technology, 2022 and 2031
  • Figure 20: Global Biotechnology & Pharmaceutical Companies Cell Analysis Market Attractiveness Analysis, by Technology, 2023-2031
  • Figure 21: Global Biotechnology & Pharmaceutical Companies Cell Analysis Market (US$ Mn), by Flow Cytometry, 2017-2031
  • Figure 22: Global Biotechnology & Pharmaceutical Companies Cell Analysis Market (US$ Mn), by Image-based Cytometry/Microscopy, 2017-2031
  • Figure 23: Global Biotechnology & Pharmaceutical Companies Cell Analysis Market (US$ Mn), by Biochemical Assays, 2017-2031
  • Figure 24: Global Biotechnology & Pharmaceutical Companies Cell Analysis Market (US$ Mn), by Mass Spectrometry, 2017-2031
  • Figure 25: Global Biotechnology & Pharmaceutical Companies Cell Analysis Market Analysis and Forecast, by Workplace, 2022 and 2031
  • Figure 26: Global Biotechnology & Pharmaceutical Companies Cell Analysis Market Attractiveness Analysis, by Workplace, 2023-2031
  • Figure 27: Global Biotechnology & Pharmaceutical Companies Cell Analysis Market (US$ Mn), by Target Identification, 2017-2031
  • Figure 28: Global Biotechnology & Pharmaceutical Companies Cell Analysis Market (US$ Mn), by Hit Generation & Lead Identification, 2017-2031
  • Figure 29: Global Biotechnology & Pharmaceutical Companies Cell Analysis Market (US$ Mn), by Lead Optimization, 2017-2031
  • Figure 30: Global Biotechnology & Pharmaceutical Companies Cell Analysis Market (US$ Mn), by In Vitro Preclinical Studies, 2017-2031
  • Figure 31: Global Biotechnology & Pharmaceutical Companies Cell Analysis Market (US$ Mn), by In Vivo Preclinical Studies, 2017-2031
  • Figure 32: Global Biotechnology & Pharmaceutical Companies Cell Analysis Market (US$ Mn), by Clinical Studies, 2017-2031
  • Figure 33: Global Cell Analysis Market Value Share Analysis, by Region, 2022 and 2031
  • Figure 34: Global Cell Analysis Market Attractiveness Analysis, by Region, 2023-2031
  • Figure 35: U.S. Cell Analysis Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 36: U.S. Cell Analysis Market Value Share Analysis, by End-user, 2022 and 2031
  • Figure 37: U.S. Cell Analysis Market Attractiveness Analysis, by End-user, 2023-2031
  • Figure 38: U.S. Biotechnology & Pharmaceutical Companies Cell Analysis Market Value Share Analysis, by Therapeutic Area, 2022 and 2031
  • Figure 39: U.S. Biotechnology & Pharmaceutical Companies Cell Analysis Market Attractiveness Analysis, by Therapeutic Area, 2023-2031
  • Figure 40: U.S. Biotechnology & Pharmaceutical Companies Cell Analysis Market Value Share Analysis, by Technology, 2022 and 2031
  • Figure 41: U.S. Biotechnology & Pharmaceutical Companies Cell Analysis Market Attractiveness Analysis, by Technology, 2023-2031
  • Figure 42: U.S. Biotechnology & Pharmaceutical Companies Cell Analysis Market Value Share Analysis, by Workplace, 2022 and 2031
  • Figure 43: U.S. Biotechnology & Pharmaceutical Companies Cell Analysis Market Attractiveness Analysis, by Workplace, 2023-2031
  • Figure 44: Europe Cell Analysis Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 45: Europe Cell Analysis Market Value Share Analysis, by End-user, 2022 and 2031
  • Figure 46: Europe Cell Analysis Market Attractiveness Analysis, by End-user, 2023-2031
  • Figure 47: Europe Biotechnology & Pharmaceutical Companies Cell Analysis Market Value Share Analysis, by Therapeutic Area, 2022 and 2031
  • Figure 48: Europe Biotechnology & Pharmaceutical Companies Cell Analysis Market Attractiveness Analysis, by Therapeutic Area, 2023-2031
  • Figure 49: Europe Biotechnology & Pharmaceutical Companies Cell Analysis Market Value Share Analysis, by Technology, 2022 and 2031
  • Figure 50: Europe Biotechnology & Pharmaceutical Companies Cell Analysis Market Attractiveness Analysis, by Technology, 2023-2031
  • Figure 51: Europe Biotechnology & Pharmaceutical Companies Cell Analysis Market Value Share Analysis, by Workplace, 2022 and 2031
  • Figure 52: Europe Biotechnology & Pharmaceutical Companies Cell Analysis Market Attractiveness Analysis, by Workplace, 2023-2031
  • Figure 53: Europe Biotechnology & Pharmaceutical Companies Cell Analysis Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 54: Europe Biotechnology & Pharmaceutical Companies Cell Analysis Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 55: China Cell Analysis Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 56: China Cell Analysis Market Value Share Analysis, by End-user, 2022 and 2031
  • Figure 57: China Cell Analysis Market Attractiveness Analysis, by End-user, 2023-2031
  • Figure 58: China Biotechnology & Pharmaceutical Companies Cell Analysis Market Value Share Analysis, by Therapeutic Area, 2022 and 2031
  • Figure 59: China Biotechnology & Pharmaceutical Companies Cell Analysis Market Attractiveness Analysis, by Therapeutic Area, 2023-2031
  • Figure 60: China Biotechnology & Pharmaceutical Companies Cell Analysis Market Value Share Analysis, by Technology, 2022 and 2031
  • Figure 61: China Biotechnology & Pharmaceutical Companies Cell Analysis Market Attractiveness Analysis, by Technology, 2023-2031
  • Figure 62: China Biotechnology & Pharmaceutical Companies Cell Analysis Market Value Share Analysis, by Workplace, 2022 and 2031
  • Figure 63: China Biotechnology & Pharmaceutical Companies Cell Analysis Market Attractiveness Analysis, by Workplace, 2023-2031
  • Figure 64: Rest of the World Cell Analysis Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 65: Rest of the World Cell Analysis Market Value Share Analysis, by End-user, 2022 and 2031
  • Figure 66: Rest of the World Cell Analysis Market Attractiveness Analysis, by End-user, 2023-2031
  • Figure 67: Rest of the World Biotechnology & Pharmaceutical Companies Cell Analysis Market Value Share Analysis, by Therapeutic Area, 2022 and 2031
  • Figure 68: Rest of the World Biotechnology & Pharmaceutical Companies Cell Analysis Market Attractiveness Analysis, by Therapeutic Area, 2023-2031
  • Figure 69: Rest of the World Biotechnology & Pharmaceutical Companies Cell Analysis Market Value Share Analysis, by Technology, 2022 and 2031
  • Figure 70: Rest of the World Biotechnology & Pharmaceutical Companies Cell Analysis Market Attractiveness Analysis, by Technology, 2023-2031
  • Figure 71: Rest of the World Biotechnology & Pharmaceutical Companies Cell Analysis Market Value Share Analysis, by Workplace, 2022 and 2031
  • Figure 72: Rest of the World Biotechnology & Pharmaceutical Companies Cell Analysis Market Attractiveness Analysis, by Workplace, 2023-2031